LAUSR

The heterogeneity of hormone receptor (HR)‐positive, HER2‐negative early breast cancers reinforces the importance of individualized, risk‐adapted treatment approaches. Numerous factors contribute to the risk for recurrence, including clinical tumor features, individual biomarkers, and genomic risk. Current standard approaches for patients with HR‐positive, HER2‐negative, early stage disease focus on endocrine therapy and chemotherapy. The specific treatment regimen and duration of adjuvant therapy should be selected based on accurate risk assessment, tolerability of available therapies, and consideration for patient preferences. For patients with high‐risk features, such as highly proliferative tumors, large tumor size, and significant nodal involvement, the risk for recurrence remains clinically significant despite appropriate adjuvant treatment with current standards of care. This has driven investigation into novel treatment approaches, including the addition of cyclin‐dependent kinase 4 and 6 inhibitors to adjuvant endocrine therapy. Cyclin‐dependent kinase 4 and 6 inhibition has demonstrated significant efficacy in patients with high‐risk, HR‐positive, HER2‐negative, nonmetastatic breast cancer and now offers a new strategy to greatly improve outcomes in this difficult to treat patient population.;